TABLE 4. Occurrence of sentinel events in each bile acid group.
| Sentinel event | Frequency overall follow‐upa, % (n/N) | Ten‐year cumulative incidence (95% CI) | p |
|---|---|---|---|
| Cholangitis | |||
| ≤40 μmol/L group | 34.9% (15 of 43) | 47.9% (25.9%–67.0%) | 0.517 |
| >40 μmol/L group | 30.9% (29 of 94) | 35.4% (24.9%–46.1%) | |
| Fracture | |||
| ≤40 μmol/L group | 0.0% (0 of 43) | 0% | 0.200 |
| >40 μmol/L group | 4.3% (4 of 94) | 5.9% (1.8%–13.8%) | |
| New‐onset splenomegalyb | |||
| ≤40 μmol/L group | 18.2% (6 of 33) | 29.1% (9.4%–52.7%) | 0.001 |
| >40 μmol/L group | 58.5% (24 of 41) | 66.5% (46.4%–80.5%) | |
| New‐onset thrombocytopeniab | |||
| ≤40 μmol/L group | 25.0% (9 of 36) | 34.7% (15.4%–54.9%) | 0.156 |
| >40 μmol/L group | 43.1% (25 of 58) | 48.4% (33.7%–61.7%) | |
| New‐onset ascitesb | |||
| ≤40 μmol/L group | 2.6% (1 of 38) | 2.8% (0.2%–12.6%) | 0.048 |
| >40 μmol/L group | 16.3% (13 of 80) | 18.6% (10.4%–28.7%) | |
| GI bleed | |||
| ≤40 μmol/L group | 2.3% (1 of 43) | 5.7% (0.3%–23.7%) | 0.031 |
| >40 μmol/L group | 16.0% (15 of 94) | 18.5% (10.3%–28.5%) | |
| New‐onset CEPHb | |||
| ≤40 μmol/L group | 33.3% (9 of 27) | 41.2% (19.1%–62.2%) | 0.038 |
| >40 μmol/L group | 64.7% (22 of 34) | 68.8% (48.5%–82.4%) | |
| Transplant/death | |||
| ≤40 μmol/L group | 4.7% (2 of 43) | 8.5% (1.1%–26.1%) | 0.001 |
| >40 μmol/L group | 31.9% (30 of 94) | 42.9% (28.6%–56.4%) |
a
Median follow‐up: 4.7 years (range 0–13.9 years).
b
Participants with CEPH (n = 76), splenomegaly (n = 63), thrombocytopenia (n = 43), or ascites (n = 19) at 6 months following KP were excluded from respective analysis of incident events.